ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Clarithromycin

Also written as “clarithromycin”, “Clarithromycin ER 500 mg tablets” and “Clarithromycin 500mg”.

Its studies are mostly in Mycobacterium avium-intracellulare Infection · Infections · HIV Infections · Bronchiectasis · Crohn Disease, led by 19 companies.

Drug pageClarithromycin: every studyMany companies study it; this page follows only the 39 they lead. All 152 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Mar 22, 200839 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbottits history only50 open or runningphase 3since Mar 22, 2008Nov 2, 1999none ahead
Sun Pharmaceutical Industriesits history only50 open or runningphase 1since Oct 15, 2008Oct 15, 2008none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Feb 2, 2009Feb 2, 2009none ahead
Pfizerits history only30 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Viatrisits history only30 open or runningphase 1since Mar 31, 2008Mar 31, 2008none ahead
Boehringer Ingelheimits history only20 open or runningphase 1since Nov 2, 1999Nov 2, 1999none ahead
Hikma Pharmaceuticalsits history only20 open or runningno phasesince Sep 20, 2007Sep 20, 2007none ahead
HK inno.Nits history only20 open or runningphase 1since Jan 7, 2014Jan 7, 2014none ahead
Johnson & Johnsonits history only20 open or runningphase 1since Jan 15, 2015Jan 15, 2015none ahead
Novartisits history only20 open or runningphase 1since Apr 13, 2009Apr 13, 2009none ahead
Italfarmaco10 open or runningphase 1since Apr 26, 2023Apr 26, 2023none ahead

Also a collaborator on its studies: Genpharm ULC.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Italfarmaco only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 26, 2023First study: phase 1 study in Drug Drug InteractionFirst studyNCT05845567 · 20 enrolled · Portugal

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule

Studies

The one study Italfarmaco leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05845567Drug Drug Interaction · Portugal1CompletedMay 8, 202220

How it is read

Names in the registry

  • “Clarithromycin”, 23 entries
  • “clarithromycin”, 2 entries
  • “Clarithromycin ER 500 mg tablets”, 2 entries
  • “Clarithromycin 500mg”, 2 entries
  • “RSS0343 Tablet; Clarithromycin Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.